Wolf VL, Ryan MJ. Autoimmune disease-associated hypertension. Curr Hypertens Rep. 2019;21:10.

Article  PubMed  PubMed Central  Google Scholar 

•• Conrad N, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet Lond Engl. 2022;400:733–43. Findings from this study show that despite improvements in the management of AD, these diseases remain associated with increased CV mortality and CV complications.

Article  Google Scholar 

Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77–95.

Article  PubMed  Google Scholar 

Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses’ health study. Arthritis Care Res. 2009;61:1396–402.

Article  Google Scholar 

Lu X, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and Meta-analysis. Int Immunopharmacol. 2021;94:107466.

Article  CAS  PubMed  Google Scholar 

Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71:1524–9.

Article  PubMed  Google Scholar 

Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211. https://doi.org/10.3390/ijms18102211. PMID: 29065479; PMCID: PMC5666891.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogdie A, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–32.

Article  PubMed  Google Scholar 

• Sun G, et al. Long-term risk of heart failure and other adverse cardiovascular outcomes in primary Sjögren’s syndrome. J Intern Med. 2022. https://doi.org/10.1111/joim.13595. This study compared Danish patients with primary Sjogren's syndrom diagnosed between 1996 and 2018 to the general population. It revealed a higher rate of incident heart failure and other cardiovascular outcomes in patients with Sjogren's syndrome.

Article  PubMed  Google Scholar 

Houben E, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatol Oxf Engl. 2018;57:555–62.

Article  Google Scholar 

Mercuzot C, et al. Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis. Autoimmun Rev. 2021;20:102708.

Article  CAS  PubMed  Google Scholar 

Hadwen B, Stranges S, Barra L. Risk factors for hypertension in rheumatoid arthritis patients-A systematic review. Autoimmun Rev. 2021;20(4):102786. https://doi.org/10.1016/j.autrev.2021.102786. Epub 2021 Feb 18. PMID: 33609791.

Article  CAS  PubMed  Google Scholar 

Hallajzadeh J, et al. The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta-analysis of observational studies. Lupus. 2018;27:899–912.

Article  CAS  PubMed  Google Scholar 

Choudhary S, Patel R, Pradhan D, Deval R, Singh H, Thomas G, Jain AK. Psoriasis and cardiovascular disorders: association or epiphenomenon? Meta-analysis of observational studies. 3 Biotech. 2020;10(3):104. https://doi.org/10.1007/s13205-020-2089-6. Epub 2020 Feb 7. PMID: 32099745; PMCID: PMC7007463.

Article  PubMed  PubMed Central  Google Scholar 

Munguia-Realpozo P, et al. Systemic lupus erythematosus and hypertension. Autoimmun Rev. 2019;18:102371.

Article  PubMed  Google Scholar 

Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun. 2017;82:1–12.

Article  PubMed  Google Scholar 

Ballocca F, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22:1435–41.

Article  PubMed  Google Scholar 

Bartoloni E, et al. The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2018;36(Suppl 112):113–20.

PubMed  Google Scholar 

Roubille C, et al. Impact of cardiovascular risk factors on the occurrence of cardiovascular events in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. J Clin Med. 2021;10:2299.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [abstract]. Symposium on Systematic Reviews: Beyond the Basics. 2000 Jul 3-5. UK: Oxford; 2000. p. 15.

Duval S, Tweedie RA. Nonparametric trim and fill method of accounting for publication bias in meta-analysis. J Am Stat AssocJ AMER Stat ASSN. 2000;95:89–98.

Google Scholar 

Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31:433–42.

Article  CAS  PubMed  Google Scholar 

Juarez M, et al. Cardiovascular risk factors in women with primary Sjögren’s syndrome: United Kingdom primary Sjögren’s syndrome registry results. Arthritis Care Res. 2014;66:757–64.

Article  CAS  Google Scholar 

Casian M, Jurcut C, Dima A, Mihai A, Stanciu S, Jurcut R. Cardiovascular disease in primary sjögren’s syndrome: raising clinicians’ awareness. Front Immunol. 2022;9(13):865373. https://doi.org/10.3389/fimmu.2022.865373. PMID: 35757738; PMCID: PMC9219550.

Article  CAS  Google Scholar 

de Leeuw K, et al. Patients with Wegener’s granulomatosis: a long-term follow-up study. Clin Exp Rheumatol. 2010;28:18–23.

PubMed  Google Scholar 

Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0117952.

Article  PubMed  PubMed Central  Google Scholar 

Hu MY, Yang Q, Zheng J. The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms. Clin Exp Dermatol. 2020;45:836–40.

Article  CAS  PubMed  Google Scholar 

Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial dysfunction in patients with rheumatoid arthritis: the role of hypertension. Curr Hypertens Rep. 2020;22:56.

Article  CAS  PubMed  Google Scholar 

Lee M-S, Chang C-H, Lin R-Y, Lai M-S. Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan. Pharmacoepidemiol Drug Saf. 2016;25:133–40.

Article  CAS  PubMed  Google Scholar 

Riley RD, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med. 2008;27:1870–93.

Article  PubMed  Google Scholar 

Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE–mechanisms and management. Nat Rev Rheumatol. 2012;8:214–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roubille F, Kritikou EA, Roubille C, Tardif J-C. Emerging anti-inflammatory therapies for atherosclerosis. Curr Pharm Des. 2013;19:5840–9.

Article  CAS  PubMed  Google Scholar 

Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124:315–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goodson NJ, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52:2293–9.

Article  CAS  PubMed  Google Scholar 

Arkema EV, Svenungsson E, Von Euler M, Sjöwall C, Simard JF. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis. 2017;76:1544–9.

Article  PubMed  Google Scholar 

Ikdahl E, et al. Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases. Int J Cardiol. 2019;274:311–8.

Article  PubMed  Google Scholar 

SFHTA. Recommandations de la SFHTA. SFHTA. https://www.sfhta.eu/hta-en-france/recommandations/recommandations-de-la-sfhta/. Accessed 20 May 2024.

• Mancia Chairperson G, et al. ESH Guidelines for the management of arterial hypertension. the task force for the management of arterial hypertension of the european society of hypertension endorsed by the european renal association (ERA) and the international society of hypertension (ISH). J Hypertens. 2023. https://doi.org/10.1097/HJH.0000000000003480. This paper report the current guidelines for the management of arterial hypertension, with a few specific recommendations for AD, such as reducing inflammation, limiting the use of NSAIDs and using calcium channel blockers and renin-angiotensin-aldosterone system inhibitors.

Article  Google Scholar 

Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.

Article  PubMed  Google Scholar 

Peters MJL, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31.

Article  CAS  PubMed  Google Scholar 

Roubille C, et al. Evidence-based recommendations for the management of comorbidities in r